Royalty Pharma
Royalty Pharma is a buyer of biopharmaceutical royalties and a funder of life sciences innovation. The firm describes itself as the world’s largest buyer of biopharma royalties, providing tailored funding solutions and partnerships to biotechnology companies, global pharmaceuticals and academic/non-profit institutions.
Royalty Pharma
Services
Acquisition of existing royalties
Purchases royalty interests in approved and commercial-stage biopharmaceutical products to provide upfront capital to sellers.
Synthetic royalties
Provides customized financing arrangements that replicate royalty-like economic exposure without transferring an existing royalty asset.
Launch and development capital
Provides capital to support late-stage development and product launch activities for novel therapeutics.
Facilitating M&A
Works with partners to facilitate mergers, acquisitions or other corporate transactions that involve royalty interests or product-level economics.
Tailored funding solutions and partnership structuring
Customizes funding arrangements to create mutually beneficial commercial and financing outcomes for partners across the biopharma ecosystem.
Accelerating Bio‑Innovation conference (programming & convening)
Organizes an invitation-only interdisciplinary conference that convenes academic, industry and investor leaders to discuss translational science and drug development.
Acquisition of existing royalties
Purchases royalty interests in approved and commercial-stage biopharmaceutical products to provide upfront capital to sellers.
Synthetic royalties
Provides customized financing arrangements that replicate royalty-like economic exposure without transferring an existing royalty asset.
Launch and development capital
Provides capital to support late-stage development and product launch activities for novel therapeutics.
Facilitating M&A
Works with partners to facilitate mergers, acquisitions or other corporate transactions that involve royalty interests or product-level economics.
Tailored funding solutions and partnership structuring
Customizes funding arrangements to create mutually beneficial commercial and financing outcomes for partners across the biopharma ecosystem.
Accelerating Bio‑Innovation conference (programming & convening)
Organizes an invitation-only interdisciplinary conference that convenes academic, industry and investor leaders to discuss translational science and drug development.